| Literature DB >> 30524616 |
Dorota Radkowiak1, Anna Zychowicz1, Michał Wysocki1,2, Anna Lasek1, Piotr Major1,2, Michał Pędziwiatr1,2, Piotr Budzyński1, Marcin Dembiński1, Jadwiga Dworak1, Andrzej Budzynski1,2.
Abstract
INTRODUCTION: Throughout our 20 years of experience, we have used several different techniques for laparoscopic splenectomy (LS). However, two methods have been used most frequently: "vessels first" and "hilar transection". AIM: To evaluate the outcomes of LS performed with these two different approaches.Entities:
Keywords: hilar transection; laparoscopy; morbidity; mortality; spleen; splenectomy; vessels first
Year: 2018 PMID: 30524616 PMCID: PMC6280088 DOI: 10.5114/wiitm.2018.76071
Source DB: PubMed Journal: Wideochir Inne Tech Maloinwazyjne ISSN: 1895-4588 Impact factor: 1.195
Photo 1Laparoscopic splenectomy performed according to the “vessels first” approach. The entire splenic hilum is dissected together with the spleen from the pancreatic tail
S – spleen, H – splenic hilum, P – pancreas.
Photo 2Laparoscopic splenectomy performed according to the “hilar transection” approach. The splenic hilum is transected at the level of the splenic parenchyma with an energy device
S – spleen, H – splenic hilum, P – pancreas
Figure 1Flowchart of patients through the study
Indications for LS
| Indication | Total | Group 1 | Group 2 | |||
|---|---|---|---|---|---|---|
| Size of the spleen, median (IQR) [cm] | Size of the spleen, median (IQR) [cm] | Size of the spleen, median (IQR) [cm] | ||||
| ITP | 254 (53.47) | 11.5 (10–13) | 99 (52.66) | 11 (10–13) | 155 (54.01) | 12 (10–13) |
| Lymphoma | 101 (21.26) | 19 (17–23) | 43 (22.88) | 20 (18–27) | 58 (20.21) | 17 (15.5–20) |
| Spherocytosis | 32 (6.74) | 17.5 (15–20) | 15 (7.97) | 18 (15–22) | 17 (5.93) | 17 (16–20) |
| Autoimmune anemia | 23 (4.84) | 15 (14–17) | 9 (4.79) | 17 (15–17) | 14 (4.88) | 14 (12.5–17) |
| Tumor | 20 (4.21) | 14 (11–15.5) | 1 (0.54) | 17 (17–17) | 19 (6.63) | 14 (10–15) |
| Splenomegaly | 22 (4.63) | 18 (16–20) | 12 (6.38) | 20 (18–30) | 10 (3.48) | 16.5 (15–18) |
| Leukemia | 9 (1.89) | 18 (17–22) | 5 (2.66) | 20 (17–25) | 4 (1.39) | 17.5 (14.75–20) |
| Other: | 14 (2.95) | 15 (12–20) | 4 (2.13) | 25 (20–35) | 10 (3.48) | 14.5 (11–15.5) |
| Sarcoidosis | 4 | 0 | 4 | |||
| Splenic artery aneurysm | 3 | 1 | 2 | |||
| Osteomyelofibrosis | 2 | 2 | 0 | |||
| Splenic cyst | 4 | 0 | 4 | |||
| Gaucher disease | 1 | 1 | 0 | |||
| Total | 475 (100) | 14 (11–17) | 188 | 15 (11–20) | 287 | 13 (11–17) |
Patients’ characteristics
| Parameter | Group 1 | Group 2 |
|
|---|---|---|---|
| Number of patients | 188 | 287 | – |
| Age [years]: | 0.001 | ||
| Median | 40 | 50 | |
| IQR | 23–55.5 | 31–60 | |
| Range | 15–84 | 17–84 | |
| Female, | 124 (65.96) | 179 (62.37) | 0.426 |
| Male, | 64 (34.04) | 108 (37.63) | |
| ASA 1, | 43 (22.87) | 68 (23.69) | 0.804 |
| ASA 2, | 58 (30.85) | 81 (28.22) | |
| ASA 3, | 49 (26.06) | 85 (29.62) | |
| ASA 4, | 38 (20.21) | 53 (18.47) | |
| Size of the spleen [cm]: | < 0.001 | ||
| Median | 15 | 13 | |
| IQR | 11–20 | 11–17 | |
| Range | 9–37 | 4–30 |
Mann-Whitney test
Pearson’s χ2 test.
Analysis of intraoperative parameters in subgroups
| Parameter | Group 1 | Group 2 |
|
|---|---|---|---|
| Operative time [min]: | < 0.001 | ||
| Median | 135 | 90 | |
| IQR | 100–160 | 70–120 | |
| Range | 50–240 | 25–280 | |
| Intraoperative blood loss [ml]: | < 0.001 | ||
| Median | 100 | 50 | |
| IQR | 50–400 | 20–100 | |
| Range | 10–1200 | 0–1500 | |
| Need for blood transfusion, | 19 (10.11) | 15 (5.23) | 0.044 |
| Conversion, | 12 (6.38) | 3 (1.05) | 0.003 |
| Intraoperative complications, | 14 (7.45) | 13 (4.53) | 0.179 |
Mann-Whitney test
Pearson’s χ2 test
χ2 test with Yates’ correction.
Intraoperative adverse events and reasons for conversions
| Intraoperative adverse events | Group 1 | Group 2 |
|---|---|---|
| Accidental injury of intra-abdominal organ: | ||
| Stomach | 3 (1.59%) | 1 (0.35%) |
| Splenic flexure | 0 | 2 (0.69%) |
| Diaphragm (sutured without chest tube) | 2 (1.06%) | 0 |
| Small bowel | 0 | 1 (0.35%) |
| Pancreatic tail | 0 | 1 (0.35%) |
| Bladder (Pfannenstiel incision) | 1 (0.53%) | 0 |
| Massive bleeding: | ||
| Managed laparoscopically | 2 (1.06%) | 4 (1.39%) |
| Requiring conversion | 2 (1.06%) | 3 (1.05%) |
| Rupture of the retrieval bag | 4 (2.13%) | 1 (0.35%) |
| Total | 14 (6.38%) | 13 (4.53%) |
|
|
|
|
| Bleeding | 2 (1.06%) | 3 (1.05%) |
| Technical problems | 4 (2.13%) | 0 |
| Infiltration of surrounding structures | 4 (2.13%) | 0 |
| Spleen’s friability | 1 (0.53%) | 0 |
| Size of the spleen | 1 (0.53%) | 0 |
| Total | 12 (7.45%) | 3 (1.05%) |
Analysis of secondary outcomes in subgroups
| Outcome | Group 1 | Group 2 |
|
|---|---|---|---|
| Postoperative morbidity | 21 (11.17%) | 19 (6.62%) | 0.081 |
| Complications related to injury of the pancreas | 10 (5.32%) | 4 (1.39%) | 0.028 |
| Reoperation | 8 (4.25%) | 11 (3.83%) | 0.635 |
| Mortality | 0 | 1 | – |
| Length of stay [days]: | 0.175 | ||
| Median | 4 | 5 | |
| IQR | 3–6 | 4–6 | |
| Range | 3–99 | 2–36 |
Pearson’s χ2 test
χ2 test with Yates’ correction
Mann-Whitney test.
Perioperative (≤ 30 days) complications according to Clavien-Dindo grading
| C-D | Complications | Group 1 | Group 2 |
|---|---|---|---|
| 5 | Massive intraoperative blood loss. Reoperation for recurrent hemorrhage (patient death) | 0 | 1 (0.35%) |
| 4b | Pancreatic fistula with abscess and secondary perforation of splenic flexure. Multiple reoperations. Cardiorespiratory failure (ICU stay) | 1 (0.53%) | 0 |
| 3b | Postoperative bleeding (relaparoscopy) | 2 (1.06%) | 4 (1.39%) |
| Subphrenic abscess (reoperation) | 3 (1.59%) | 2 (0.69%) | |
| Acute pancreatitis (reoperation) | 1 (0.53%) | 1 (0.35%) | |
| Perforation of the fundus of the stomach probably due to thermal injury (reoperation on 8th postoperative day) | 0 | 1 (0.35%) | |
| Subphrenic hematoma (operative drainage) | 0 | 1 (0.35%) | |
| Thrombosis of superior mesenteric artery (revascularization) | 0 | 1 (0.35%) | |
| Pancreatic fistula | 1 (0.53%) | 0 | |
| 3a | Subphrenic abscess (percutaneous drainage) | 1 (0.53%) | 1 (0.35%) |
| Port-site bleeding (suture ligation under local anesthesia) | 0 | 1 (0.35%) | |
| Pelvic hematoma (percutaneous drainage) | 1 (0.53%) | 0 | |
| Pneumothorax (chest tube) | 0 | 1 (0.35%) | |
| 2 | Fever of unknown origin | 4 (2.13%) | 3 (1.05%) |
| Pulmonary infection | 1 (0.53%) | 1 (0.35%) | |
| Urinary tract infection | 1 (0.53%) | 0 | |
| Superior mesenteric vein thrombosis | 1 (0.53%) | 0 | |
| Subphrenic hematoma | 0 | 1 (0.35%) | |
| 1 | Subphrenic fluid collection | 3 (1.59%) | 0 |
| Pneumothorax (spontaneous resolution) | 1 (0.53%) | 0 | |
| Total | 21 (11.17%) | 19 (6.62%) |